Aethlon Medical Confirms HIV Treatment Presentation.

Health/Medical Writers

SAN DIEGO--(BW HealthWire)--Jan. 3, 2001

Aethlon Medical, Inc., (OTCBB: AEMD) confirmed today that it has accepted an invitation to present its HIV-Hemopurifier(TM) treatment technology at Cambridge Healthtech Institute's Seventh Annual Blood Product Safety Conference on Tuesday, February 6, 2001.

The presentation will mark the introduction of Aethlon's HIV-Hemopurifier to the medical community and will include an updated report on the development status of the HIV-Hemopurifier treatment technology. The HIV-Hemopurifier is designed to rapidly reduce the body burden of the HIV virus through the direct physical removal of the virus in circulation. The technology is targeted to improve the performance of leading HIV-AIDS drugs and is also anticipated to be utilized as a non-toxic treatment for patients who are unresponsive to established pharmaceutical regimens. Aethlon plans to initiate human trials of the HIV-Hemopurifier within the year.

Other conference participants include: American Red Cross, Boston Biomedica, Inc., Canadian Blood Services, Chiron Corporation, Japanese Red Cross, National Institute of Health (NIH), Pharmacia Biotech, and the United States Army Medical Corp.

About Aethlon Medical

Aethlon Medical is applying its proprietary platform technology known as the Hemopurifier(TM) to develop an extracorporeal therapeutic treatment for AIDS. Recent pre-clinical trials have documented the rapid removal of up to 70% of the circulating HIV virus during one sixty-minute application. Products already developed from the Hemopurifier platform are designed to treat Lead Poisoning, Iron Overload, and curb the side effects of cisplatin based Chemotherapy.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. (the "Company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the Company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the Company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 1-800-SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's website located at http://www.sec.gov.